What question did this study set out to answer?

The research aims to evaluate the response to immunotherapy in recurrent endometrial and cervical cancer within radiated fields.

April 4, 2026Gynecologic Oncology1 citationsOpen Access

Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer

JCJulia ChalifCleveland Clinic MMMolly MortonWashington University in St. Louis AGAnna GonzalezThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Key Points

The research aims to evaluate the response to immunotherapy in recurrent endometrial and cervical cancer within radiated fields.
Analyzed patient outcomes based on recurrence location (in-field vs. out-of-field)
Compared response rates for endometrial and cervical cancers
Assessed complete response rates for in-field cases
Immunotherapy showed activity for tumors recurred in prior radiated fields
Endometrial cancer in-field recurrences had higher complete response rates
Cervical cancer outcomes were similar regardless of recurrence location

Abstract

Immunotherapy remained active in tumors recurring within prior radiated fields. Outcomes were similar for in-field and out-of-field recurrences in EC and CC. Endometrial cancers recurring in-field had higher complete response rates. Cervical cancer outcomes were comparable across recurrence locations.

AIに質問

Bookmark

View Full Paper